RxSight, Inc.

RXST

Nasdaq; healthcare; SIC 3851, Ophthalmic Goods; CIK 0001111485

A

strongest fifth of 370 graded peers in healthcare

rank 60 of 370; percentile 16.0; sampling error 2.5 points; lower is stronger

A B C D E

A, the bull



Scoreboard	
Profitability	D percentile 63.4
Solvency	A/B percentile 21.8
Growth and financing	A/B percentile 21.8
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $311.8M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered; fortress balance sheet
Inputs computable	9 of 14
Graded from	filings received through Feb 25, 2026 245 days before the rescan; latest periodic filing 10-Q received Aug 5, 2026
Last close	$4.91 2026-10-27; market equity $204.0M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 25, 2026

RxSight, Inc. is a commercial-stage medical technology company dedicated to providing high-quality customized vision to patients following cataract surgery. Our proprietary RxSight® Light Adjustable Lens system ("RxSight system") is the first and only commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system is comprised of our RxSight Light Adjustable Lens®(LAL®/LAL+®, collectively the "LAL"), RxSight Light Delivery Device ("LDD?") and related accessories.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 63.4						
Gross profitability	33.0%	32.3%		43.8	369	2025-12-31
Return on invested capital	not computable	9.3%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(7.4%)	(6.6%)	52.0	805	2025-12-31
Gross margin stability, five years	20.5 pts	2.8 pts	94.6	242	2025-12-31
Solvency, sleeve percentile 21.8					
Twelve-month failure probability	0.05%	0.07%	34.7	246	2026-06-30
Altman Z double-prime	5.56	(0.33)	16.7	751	2025-12-31
Net debt to EBITDA	not computable	1.82x			
EBITDA must exceed $100,000					
Interest coverage	not computable	(4.51x)			
interest expense must exceed $100,000					
Current ratio	10.95x	2.94x	14.0	832	2025-12-31
Growth and financing, sleeve percentile 21.8					
Revenue growth, three-year compound	40.0%	10.1%	17.0	413	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	27.6%	2.1%	16.8	697	2025-12-31
Net share issuance, one year	1.9%	2.5%	31.6	634	2026-02-18

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 9,692,000 USD; Altman Z is not used

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
55	Treace Medical Concepts, Inc. (TMCI)	14.6	A	
56	Lantheus Holdings, Inc. (LNTH)	14.9	A	
57	Harrow, Inc. (HROW)	15.2	A	late filer
58	Edwards Lifesciences Corp. (EW)	15.4	A	
59	Vertex Pharmaceuticals Inc. MA (VRTX)	15.7	A	
60	RxSight, Inc. (RXST)	16.0	A	fortress balance sheet
61	Ensign Group, Inc. (ENSG)	16.3	A	fortress balance sheet
62	Natures Sunshine Products Inc. (NATR)	16.5	A	fortress balance sheet
63	Definium Therapeutics, Inc. (DFTX)	16.8	A	dilution
64	Alnylam Pharmaceuticals, Inc. (ALNY)	17.1	A	
65	Acadia Pharmaceuticals Inc. (ACAD)	17.3	A	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-10-27 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(18.5%)	7.7%	31
Distance from 52-week high	(62.6%)	(28.6%)	17
EBIT to enterprise value	(25.3%)	(1.5%)	22
Free cash flow yield	(9.5%)	(1.0%)	33
Book value to price	1.29	0.28	90
Sales to price	0.66	0.31	74
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(0.42)	(0.14)	31

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$13.4M
Operating cash flow, four quarters	-$22.7M
Months of runway	7.0
Days since last periodic filing	84 (10-Q received Aug 5, 2026)
Median daily dollar volume, 63 sessions	$3.9M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$103.0M	2025-12-31	2026-02-25	10-K	26-071775
2	assets	us-gaap:Assets	$311.8M	2025-12-31	2026-02-25	10-K	26-071775
3	operating income	us-gaap:OperatingIncomeLoss	-$50.1M	2023-12-31	2026-02-25	10-K	26-071775
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$48.6M	2023-12-31	2026-02-25	10-K	26-071775
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$20,000	2023-12-31	2026-02-25	10-K	26-071775
6	total debt	us-gaap:LongTermDebt	$0	2023-12-31	2024-02-28	10-K	24-022073
7	book equity	us-gaap:StockholdersEquity	$160.4M	2023-12-31	2025-02-25	10-K	25-026681
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$9.7M	2023-12-31	2025-02-25	10-K	25-026681
9	total debt	us-gaap:LongTermDebt	$40.2M	2022-12-31	2024-02-28	10-K	24-022073
10	book equity	us-gaap:StockholdersEquity	$89.9M	2022-12-31	2024-02-28	10-K	24-022073
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$11.8M	2022-12-31	2024-02-28	10-K	24-022073
12	net income	us-gaap:NetIncomeLoss	-$38.9M	2025-12-31	2026-02-25	10-K	26-071775
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$15.5M	2025-12-31	2026-02-25	10-K	26-071775
14	assets	us-gaap:Assets	$318.6M	2024-12-31	2026-02-25	10-K	26-071775
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$134.5M	2025-12-31	2026-02-25	10-K	26-071775
16	gross profit	us-gaap:GrossProfit	$98.9M	2024-12-31	2026-02-25	10-K	26-071775
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$139.9M	2024-12-31	2026-02-25	10-K	26-071775
18	gross profit	us-gaap:GrossProfit	$53.8M	2023-12-31	2026-02-25	10-K	26-071775

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$89.1M	2023-12-31	2026-02-25	10-K	26-071775
20	gross profit	us-gaap:GrossProfit	$21.3M	2022-12-31	2025-02-25	10-K	25-026681
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$49.0M	2022-12-31	2025-02-25	10-K	25-026681
22	gross profit	us-gaap:GrossProfit	$4.5M	2021-12-31	2023-03-06	10-K	23-006237
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$22.6M	2021-12-31	2023-03-06	10-K	23-006237
24	current assets	us-gaap:AssetsCurrent	$287.5M	2025-12-31	2026-02-25	10-K	26-071775
25	current liabilities	us-gaap:LiabilitiesCurrent	$26.3M	2025-12-31	2026-02-25	10-K	26-071775
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$661.0M	2025-12-31	2026-02-25	10-K	26-071775
27	operating income	us-gaap:OperatingIncomeLoss	-$48.2M	2025-12-31	2026-02-25	10-K	26-071775
28	book equity	us-gaap:StockholdersEquity	$275.7M	2025-12-31	2026-02-25	10-K	26-071775
29	liabilities	us-gaap:Liabilities	$36.1M	2025-12-31	2026-02-25	10-K	26-071775
30	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$4.1M	2023-12-31	2026-02-25	10-K	26-071775
31	interest expense	us-gaap:InterestExpense	$19,000	2025-12-31	2026-02-25	10-K	26-071775
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$3.8M	2025-12-31	2026-02-25	10-K	26-071775
33	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$16.9M	2024-12-31	2026-02-25	10-K	26-071775
34	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$5.4M	2024-12-31	2026-02-25	10-K	26-071775
35	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$41.6M	2023-12-31	2026-02-25	10-K	26-071775
36	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$4.8M	2023-12-31	2026-02-25	10-K	26-071775
37	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$58.9M	2022-12-31	2025-02-25	10-K	25-026681
38	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$2.4M	2022-12-31	2025-02-25	10-K	25-026681
39	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$3.3M	2025-12-31	2026-02-25	10-K	26-071775
40	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$38.9M	2025-12-31	2026-02-25	10-K	26-071775
41	income tax	us-gaap:IncomeTaxExpenseBenefit	$66,000	2025-12-31	2026-02-25	10-K	26-071775
42	current assets	us-gaap:AssetsCurrent	$293.8M	2024-12-31	2026-02-25	10-K	26-071775
43	current liabilities	us-gaap:LiabilitiesCurrent	$25.9M	2024-12-31	2026-02-25	10-K	26-071775
44	assets	us-gaap:Assets	$182.6M	2023-12-31	2025-02-25	10-K	25-026681
45	assets	us-gaap:Assets	$150.2M	2022-12-31	2024-02-28	10-K	24-022073
46	shares outstanding	dei:EntityCommonStockSharesOutstanding	41,266,335	2026-02-18	2026-02-25	10-K	26-071775
47	shares outstanding	dei:EntityCommonStockSharesOutstanding	40,490,542	2025-02-14	2025-02-25	10-K	25-026681

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.